The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support

The Lancet Oncology

Volumn 15, Issue 12, 2014, Pages e568-e580

  Warren, Graham W ^a,b   Sobus, Samantha ^b,c   Gritz, Ellen R ^d  

^a Department of Radiation Oncology ^*  (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; CIGARETTE SMOKE; ERLOTINIB; ISOTRETINOIN; NICOTINIC RECEPTOR; TAMOXIFEN;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL PRACTICE; COUNSELING; CYTOLOGY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NICOTINE REPLACEMENT THERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SMOKING; SMOKING CESSATION PROGRAM; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; SMOKING CESSATION; TREATMENT OUTCOME;

CELL PROLIFERATION; HUMANS; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84908569070     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70266-9     Document Type: Review

References (87)

1. The health consequences of smoking-50 years of progress: a report of the Surgeon General 2014, US Department of Health and Human Services, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
2. Land SR Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. J Clin Oncol 2012, 30:2030-2032.
3. Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thorac Oncol 2013, 8:543-548.
4. Warren GW, Marshall JR, Cummings KM, et al. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract 2013, 9:258-262.
5. Thorne D, Adamson J A review of in vitro cigarette smoke exposure systems. Exp Toxicol Pathol 2013, 65:1183-1193.
6. Shields PG Tobacco smoking, harm reduction, and biomarkers. J Natl Cancer Inst 2002, 94:1435-1444.
7. Feng S, Cao Z, Wang X Role of aryl hydrocarbon receptor in cancer. Biocim Biophys Acta 2013, 1836:197-210.
8. Portal-Nuñez S, Shankavaram UT, Rao M, et al. Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice. Cancer Res 2012, 72:5790-5800.
9. Uppstad H, Osnes GH, Cole KJ, Phillips DH, Haugen A, Mollerup S Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer 2011, 71:264-270.
10. Zhang M, Mathur A, Zhang Y, et al. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res 2012, 72:4178-4192.
11. Hussain M, Rao M, Humphries AE, et al. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 2009, 69:3570-3578.
12. Xi S, Xu H, Shan J, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest 2013, 123:1241-1261.
13. Li P, Wu WK, Wong HP, Zhang ST, Yu L, Cho CH Chloroform extract of cigarette smoke induces proliferation of human esophageal squamous-cell carcinoma cells: modulation by beta-adrenoceptors. Drug Chem Toxicol 2009, 32:175-181.
14. Liu ES, Shin VY, Ye YN, Luo JC, Wu WK, Cho CH Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Eur J Pharmacol 2005, 518:47-55.
15. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005, 26:827-834.
16. Ye YN, Wu WK, Shin VY, Cho CH A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur J Pharmacol 2005, 519:52-57.
17. Newland N, Richter A Agents associated with lung inflammation induce similar responses in NCI-H292 lung epithelial cells. Toxicol In Vitro 2008, 22:1782-1788.
18. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J Biol Chem 2003, 278:26202-26207.
19. Shao MX, Nakanaga T, Nadel JA Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 2004, 287:L420-L427.
20. Filosto S, Baston DS, Chung S, Becker CR, Goldkorn T Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol Cancer Ther 2013, 12:1579-1590.
21. Filosto S, Becker CR, Goldkorn T Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol Cancer Ther 2012, 11:795-804.
22. Samanta D, Gonzalez AL, Nagathihalli N, Ye F, Carbone DP, Datta PK Smoking attenuates transforming growth factor-β-mediated tumor suppression function through downregulation of Smad3 in lung cancer. Cancer Prev Res (Phila) 2012, 5:453-463.
23. Chang X, Ravi R, Pham V, Bedi A, Chatterjee A, Sidransky D Adenylate kinase 3 sensitizes cells to cigarette smoke condensate vapor induced cisplatin resistance. PLoS One 2011, 6:e20806.
24. Ratovitski EA δNp63α/IRF6 interplay activates NOS2 transcription and induces autophagy upon tobacco exposure. Arch Biochem Biophys 2011, 506:208-215.
25. Di Cello F, Flowers VL, Li H, et al. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer 2013, 12:90.
26. Xu L, Mao XY, Fan CF, Zheng HC MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer. Virchows Arch 2011, 459:415-422.
27. Huynh TP, Mah V, Sampson VB, et al. Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol Lung Cell Mol Physiol 2012, 302:L1150-L1158.
28. Schaal C, Chellappan SP Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res 2014, 12:14-231.
29. Warren GW, Singh AK Nicotine and lung cancer. J Carcinog 2013, 12:1.
30. Schuller HM Regulatory role of the α7nAChR in cancer. Curr Drug Targets 2012, 13:680-687.
31. Singh S, Pillai S, Chellappan S Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011, 2011:456743.
32. Momi N, Ponnusamy MP, Kaur S, et al. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through α7nAChR-mediated MUC4 upregulation. Oncogene 2013, 32:1384-1395.
33. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 2006, 103:6332-6337.
34. Warren GW, Romano MA, Kudrimoti MR, et al. Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer 2012, 131:2519-2527.
35. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update US Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008, 53:1217-1222.
36. Hanna N, Mulshine J, Wollins DS, Tyne C, Dresler C Tobacco cessation and control a decade later: American society of clinical oncology policy statement update. J Clin Oncol 2013, 31:3147-3157.
37. Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013, 19:1941-1948. the AACR Subcommittee on Tobacco and Cancer.
38. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008, 3:590-598. the National Cancer Institute of Canada Clinical Trials Group.
39. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
40. Holgersson G, Hoye E, Bergqvist M, et al. Swedish Lung Cancer Radiation Study Group: predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancer. Acta Oncol 2012, 51:759-767.
41. Kawaguchi T, Tamiya A, Tamura A, et al. Chemotherapy is beneficial for elderly patients with advanced non-small-cell lung cancer: analysis of patients aged 70-74, 75-79, and 80 or Older in Japan. Clin Lung Cancer 2012, 13:442-447.
42. Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012, 13:1161-1170.
43. Li YH, Shieh SH, Chen CY The influence of health behaviors on survival in lung cancer patients in Taiwan. Jpn J Clin Oncol 2011, 41:365-372.
44. Pirker R, Pereira JR, Szczesna A, et al. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer 2012, 77:376-382.
45. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993, 119:383-390.
46. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006, 106:2428-2436.
47. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997, 89:1782-1788.
48. Fortin A, Wang CS, Vigneault E Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2009, 74:1062-1069.
49. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012, 30:2102-2111.
50. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006, 98:441-450.
51. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer 2008, 122:1679-1683.
52. Alsadius D, Hedelin M, Johansson KA, et al. Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. Radiother Oncol 2011, 101:495-501.
53. Bittner N, Merrick GS, Galbreath RW, et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008, 72:433-440.
54. Boorjian S, Cowan JE, Konety BR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007, 177:883-887.
55. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65:669-677.
56. Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol 2004, 171:1543-1546.
57. Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342.
58. Gold EB, Flatt SW, Pierce JP, et al. Dietary factors and vasomotor symptoms in breast cancer survivors: the WHEL Study. Menopause 2006, 13:423-433.
59. Li CI, Daling JR, Porter PL, Tang MT, Malone KE Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009, 27:5312-5318.
60. Obedian E, Fischer DB, Haffty BG Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 2000, 18:2406-2412.
61. Eifel PJ, Jhingran A, Bodurka DC, Levenback C, Thames H Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol 2002, 20:3651-3657.
62. Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003, 159:161-173.
63. McCleary NJ, Niedzwiecki D, Hollis D, et al. Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer 2010, 116:957-966.
64. Park SM, Lim MK, Jung KW, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 2007, 25:4835-4843.
65. Vogelius IR, Bentzen SM A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 2012, 51:875-983.
66. Petros WP, Younis IR, Ford JN, Weed SA Effects of tobacco smoking & nicotine on cancer treatment. Pharmacotherapy 2012, 32:920-931.
67. Bjarnason GA, Mackenzie RG, Nabid A, et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 2009, 73:166-172.
68. Tobacco cessation guide for oncology providers American Society of Clinical Oncology, (accessed Feb 21, 2014). http://www.asco.org/sites/default/files/tobacco_cessation_guide.pdf.
69. Prochaska JJ, Das S, Benowitz NL Cytisine, the world's oldest smoking cessation aid. BMJ 2013, 347:f5198.
70. Goniewicz ML, Hajek P, McRobbie H Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. Addiction 2014, 109:500-507.
71. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013, 382:1629-1637.
72. Cummings KM, Dresler CM, Field JK, et al. E-cigarettes and cancer patients. J Thorac Oncol 2014, 9:438-441.
73. Gritz ER, Lam CY, Vidrine DJ, Fingeret MC Cancer prevention: tobacco dependence and its treatment. cancer: principles and practices in oncology 2011, 529-542. Lippincott Williams & Wilkins, Philadelphia. V.T. Devita, T. Lawrence, S.A. Rosenberg (Eds.).
74. Gritz ER, Dresler C, Sarna L Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005, 14:2287-2293.
75. Dresler CM, Gritz ER Smoking, smoking cessation and the oncologist. Lung Cancer 2001, 34:315-323.
76. Cataldo JK, Slaughter R, Jahan TM, Pongquan VL, Hwang WJ Measuring stigma in people with lung cancer: psychometric testing of the cataldo lung cancer stigma scale. Oncol Nurs Forum 2011, 38:E46-E54.
77. Warren GW, Marshall JR, Cummings KM, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer 2014, 120:562-569.
78. Ostroff JS, Burkhalter JE, Cinciripini PM, et al. Randomized trial of a pre-surgical scheduled reduced smoking intervention for patients newly diagnosed with cancer. Health Psychology 2014, 33:737-747.
79. Garces YI, Schroeder DR, Nirelli LM, Croghan IT, Foote RL, Hurt RD Tobacco use outcomes among patients with head and neck carcinoma treated for nicotine dependence. Cancer 2004, 101:116-124.
80. Rigotti NA, Clar C, Munafo MR, Stead LF Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev 2012, 5. CD001837.
81. Nayan S, Gupta MK, Strychowsky JE, Sommer DD Smoking cessation interventions and cessation rates in the oncology population: an updated systematic review and meta-analysis. Otolaryngol Head Neck Surg 2013, 149:200-211.
82. Toll BA, Rojewski AM, Duncan LR, et al. "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res 2014, 20:301-309.
83. Consedine NS, Horton D, Magai C, Kukafka R Breast screening in response to gain, loss, and empowerment framed messages among diverse, low-income women. J Health Care Poor Underserved 2007, 18:550-566.
84. Yach D The origins, development, effects, and future of the WHO Framework Convention on Tobacco Control: a personal perspective. Lancet 2014, 383:1771-1779.
85. Smith DR, Leggat PA An international review of tobacco smoking in the medical profession: 1974-2004. BMC Public Health 2007, 7:115.
86. Novotny TE Smoking cessation and tuberculosis: connecting the DOTS. Int J Tuberc Lung Dis 2008, 12:1103.
87. Niaura R, Chander G, Hutton H, Stanton C Interventions to address chronic disease and HIV: strategies to promote smoking cessation among HIV-infected individuals. Curr HIV/AIDS Rep 2012, 9:375-384.